NS-2359

From Self-sufficiency
Jump to: navigation, search
NS-2359
File:NStwothreefivenine.png
Systematic (IUPAC) name
(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-azabicyclo[3.2.1]octane
Identifiers
ATC code none
PubChem CID 11408320
Chemical data
Formula C15H19Cl2NO
Molar mass 300.223 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company.[1] NS-2359 was also in clinical trials for the treatment of ADHD,[2] phase II having been completed in 2007.[3] A trial exploring the effect of NS-2359 on cocaine-experienced individuals is currently ongoing.[4]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. 1.0 1.1 "NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression". 
  2. Wilens, T. E.; Klint, T.; Adler, L.; West, S.; Wesnes, K.; Graff, O.; Mikkelsen, B. (2008). "A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD". Behavioral and brain functions : BBF. 4: 24. doi:10.1186/1744-9081-4-24. PMC 2442604Freely accessible. PMID 18554401.  edit
  3. http://clinicaltrials.gov/ct2/show/NCT00467428
  4. http://clinicaltrials.gov/ct2/show/NCT00032916